150,000 Shares in Neon Therapeutics Inc (NTGN) Purchased by PointState Capital LP

PointState Capital LP purchased a new position in shares of Neon Therapeutics Inc (NASDAQ:NTGN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 150,000 shares of the company’s stock, valued at approximately $1,890,000. PointState Capital LP owned 0.53% of Neon Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. TRV GP Iii LLC acquired a new position in Neon Therapeutics during the 2nd quarter worth approximately $122,745,000. FMR LLC acquired a new position in Neon Therapeutics during the 2nd quarter worth approximately $26,746,000. Hillhouse Capital Management Ltd. acquired a new position in Neon Therapeutics during the 2nd quarter worth approximately $8,969,000. Harvard Management Co. Inc. acquired a new position in Neon Therapeutics during the 2nd quarter worth approximately $6,374,000. Finally, Laurion Capital Management LP acquired a new position in Neon Therapeutics during the 2nd quarter worth approximately $1,575,000. 65.71% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on NTGN. Cann began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set an “outperform” rating and a $20.00 price target on the stock. Oppenheimer began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set a “$11.74” rating and a $20.00 price target on the stock. Bank of America began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set a “buy” rating and a $18.00 price target on the stock. Finally, Morgan Stanley began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They set an “overweight” rating and a $23.00 price target on the stock.

Shares of NTGN opened at $9.09 on Friday. Neon Therapeutics Inc has a 52 week low of $9.00 and a 52 week high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Monday, August 6th. The company reported ($7.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($7.04). research analysts predict that Neon Therapeutics Inc will post -5.5 earnings per share for the current fiscal year.

In related news, major shareholder Access Industries Holdings Llc acquired 315,000 shares of the firm’s stock in a transaction on Friday, June 29th. The stock was purchased at an average cost of $16.00 per share, with a total value of $5,040,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Further Reading: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding NTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neon Therapeutics Inc (NASDAQ:NTGN).

Institutional Ownership by Quarter for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply